Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart diseaseSouthlake, TX, June 03, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (“AI”) powered medical technology company focused on transforming ECGs/EKGs to enable earlier detection of heart disease, today announced the grant by the United States Patent and Trademark Office (USPTO) of a foundati ...

Core Insights - Broadcom Inc. has launched the Tomahawk 6 switch series, which features the world's first 102.4 Terabits/sec switching capacity in a single chip, doubling the bandwidth of existing Ethernet switches [1][2] - The Tomahawk 6 is designed to support the next generation of scale-up and scale-out AI networks, offering energy efficiency and AI-optimized features [1][2] - The demand for Tomahawk 6 from customers and partners has been unprecedented, indicating a significant market opportunity for Broadcom [2] Product Features - Tomahawk 6 includes support for 100G/200G SerDes and co-packaged optics (CPO), providing flexibility and efficiency for AI clusters with over one million XPUs [1][3] - The switch offers advanced routing features, including Cognitive Routing 2.0, which enables global load balancing and adaptive flow control tailored for modern AI workloads [5][11] - It supports both scale-up and scale-out networking, allowing operators to utilize a unified technology stack across their AI infrastructure [6][11] Market Impact - The introduction of Tomahawk 6 is expected to alleviate network bottlenecks as AI clusters scale from tens to thousands of accelerators, providing a clear path for hyperscalers to enhance their AI infrastructure [2][7] - Multiple deployments are planned with over 100,000 XPUs using Tomahawk 6, highlighting its significance in the AI networking landscape [7] - Broadcom's commitment to open standards through the Scale Up Ethernet (SUE) Framework aims to foster an open ecosystem for AI infrastructure [9][10] Industry Collaboration - Broadcom is collaborating with various industry leaders, including AMD and Arista Networks, to enhance AI infrastructure capabilities using Tomahawk 6 [18][19] - The switch is compliant with Ultra Ethernet Consortium specifications, ensuring compatibility with modern AI transports and network topologies [11][22] - Industry analysts recognize Tomahawk 6 as a game changer for hyperscale data centers, enabling the development of scalable and efficient AI networking solutions [23][24]

NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Jeffrey Bailly, Chairman and CEO, and Ron Lataille, Sr. Vice President & CFO, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025. UFP’s fireside chat is scheduled to begin at 11:20 AM ET. About UFP Technologies, Inc. UFP Technologies is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other h ...

FORT LAUDERDALE, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- ZEFIRO METHANE CORP. (Cboe Canada: ZEFI) (Frankfurt: Y6B) (OTCQB: ZEFIF) (the “Company”, “Zefiro”, or “ZEFI”) today announced the appointments of Board of Directors member Correne Loeffler and Michael Downs as the Chair of the Audit Committee and interim Chief Financial Officer, respectively. Ms. Loeffler and Mr. Downs will execute strategies that bolster Zefiro’s long-term financial standing and help ensure that the Company continues to accelerate th ...

NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies (UFPT), today announced Jeffrey Bailly, Chairman and CEO and Ron Lataille, Sr. Vice President & CFO, will present at the East Coast IDEAS Investor Conference on Wednesday, June 11, 2025 at The Westin Times Square in New York, NY. UFP’s presentation is scheduled to begin at 7:55 AM ET. The presentation is webcast and can be accessed through the conference host’s main website: https://www.threepartadvisors.com/east-coast and in the investo ...

Core Viewpoint - Myriad Genetics, Inc. has announced early access to the FirstGene Multiple Prenatal Screen, which aims to provide a comprehensive prenatal genetic risk assessment through a single blood draw without requiring paternal testing [1][2][3] Group 1: Product Overview - The FirstGene screen combines multiple testing modalities into one assay, identifying carrier status for the pregnant individual and assessing fetal risk for genetic anomalies, including chromosomal aneuploidies and pathogenic mutations in ten severe recessive conditions [2][6] - The screen also evaluates RhD compatibility between the pregnant patient and the fetus, enhancing the overall prenatal assessment process [2][6] - The assay utilizes cell-free DNA from the pregnant person, eliminating the need for a sample from the paternal reproductive partner, which is significant as only 41.5% of male partners undergo carrier screening when the pregnant person is known to be a carrier of an autosomal recessive condition [5] Group 2: Clinical Study and Validation - The FirstGene screen will be evaluated in the CONNECTOR study, which plans to enroll over 5,000 patients across multiple clinical sites, aiming to establish clinical validity and utility in a real-world setting [3] - The screen has demonstrated over 98.6% sensitivity and 99.6% specificity across variants in both the fetus and the pregnant individual, indicating its high analytical performance [3][4] Group 3: Company Strategy and Growth Opportunity - The introduction of the FirstGene screen represents a significant growth opportunity for Myriad Genetics, expanding its prenatal portfolio and enhancing the company's position in the molecular diagnostic testing market [3][8] - Myriad Genetics is committed to advancing health and well-being through innovative molecular tests that guide treatment decisions and improve patient care [8]

Company Information - 74Software is an enterprise software group formed by the merger of Axway and SBS, specializing in mission-critical software for a data-driven world [3] - Axway has been a pioneer in enterprise integration solutions for 25 years, providing services to major brands and government agencies globally [3] - SBS focuses on empowering banks and financial institutions with a cloud-based architecture for various financial services [3] - The company serves over 11,000 clients, including more than 1,500 in the financial services sector [3] Voting Rights and Shares - As of May 31, 2025, the total number of shares is 29,746,194 [5] - The total number of theoretical voting rights is 41,294,970 [5] - The number of exercisable voting rights is 40,813,565, which includes shares with suspended voting rights [1]

Core Insights - 60 Degrees Pharmaceuticals, Inc. announced results from an insurance claims analysis indicating a significant discrepancy between the number of Americans seeking reimbursement for babesiosis-related medical costs and CDC estimates of actual cases [1][2][10] - The company is investigating the true burden of babesiosis, particularly its association with chronic fatigue, through ongoing clinical trials and studies [6][8][10] Claims Analysis - Approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs annually, while CDC estimates only 2,000 cases in 2020 [2][10] - Claims data revealed that about 31% of babesiosis cases persist longer than 30 days, with nearly half of these cases associated with chronic fatigue lasting over six months [4][10] Chronic Fatigue Insights - Babesia infections can last at least 12 months in 14% of patients, with potential relapses occurring up to 27 months later [3] - Over three years, more than 12 million U.S. adults experienced chronic fatigue lasting more than six months, yet current guidelines do not mandate babesiosis as a differential diagnosis for such fatigue [5][10] Clinical Development - The company is conducting clinical trials to evaluate the safety and efficacy of tafenoquine in treating babesiosis, with data expected in the first half of 2026 [8][10] - A new drug application (NDA) for babesiosis is anticipated to be submitted to the FDA in 2026 [8][10] Product Information - Tafenoquine, marketed as ARAKODA, was approved for malaria prophylaxis in 2018 and is available as a prescription-only medication [9][10] - The drug has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [9]

VANCOUVER, BC, June 3, 2025 /PRNewswire/ - New Found Gold Corp. (TSXV: NFG) (NYSE-A: NFGC) ("New Found Gold" or the "Company") is pleased to announce that it has closed the first tranche of its previously announced "bought deal" public offering of (i) 21,400,000 charity flow-through common shares of the Company (the "Charity Flow-Through Common Shares") that will qualify as "flow-through shares" (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) at a price of C$2.29 per Charity Flow-Th ...

Group 1 - Energi Holdings Limited proposes to acquire 51% of Tembo at a total enterprise value of US$200 million, with both parties agreeing to negotiate binding transaction documents for an early closing [1][3] - Energi, headquartered in Abu Dhabi, has annual revenues of US$1 billion and operates across multiple regions including the Middle East, Africa, South Asia, Europe, and Southeast Asia [2] - VivoPower's board is evaluating the optimal use of investment proceeds, which may include special dividends or capital returns to shareholders [4] Group 2 - VivoPower is undergoing a strategic transformation to focus on XRP digital assets, aiming to support decentralized finance infrastructure and real-world blockchain applications [5] - VivoPower operates globally with a presence in the UK, Australia, North America, Europe, the Middle East, and Southeast Asia, and has two business units: Tembo and Caret Digital [6]